Akari Therapeutics (AKTX) Gains from Sales and Divestitures (2023 - 2026)
Akari Therapeutics recorded quarterly Gains from Sales and Divestitures of $1465.0 in Q1 2026, down 96.83% quarter-over-quarter from $46277.0 in Q4 2025.
Akari Therapeutics' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $1465.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $1465.0; the TTM figure through Mar 2026 stood at $1465.0 (changed N/A YoY), while the FY2025 annual figure was $46277.0, down 99.99% from the prior year.
- Gains from Sales and Divestitures came in at $1465.0 for Q1 2026 at Akari Therapeutics, down from $46277.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $635.1 million in Q4 2024 to a low of $1465.0 in Q1 2026.
- A 4-year average of $171.4 million and a median of $43.4 million in 2023 frame the typical range for Gains from Sales and Divestitures.
- Across the five-year window, Gains from Sales and Divestitures soared 1364.6% in 2024 and sank 99.99% in 2025, its largest moves.
- Akari Therapeutics' Gains from Sales and Divestitures stood at $43.4 million in 2023, then jumped by 1364.6% to $635.1 million in 2024, then tumbled by 99.99% to $46277.0 in 2025, then tumbled by 96.83% to $1465.0 in 2026.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $1465.0, $46277.0, and $40000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,465.00 |
| Mar 31, 2026 | 1,465.00 |
| Dec 31, 2025 | 46,277.00 |
| Dec 31, 2025 | 46,277.00 |
| Sep 30, 2025 | 40,000.00 |
| Sep 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Dec 31, 2024 | 635.10 Mn |
| Dec 31, 2024 | 635.10 Mn |
| Sep 30, 2024 | 383.28 Mn |
| Sep 30, 2024 | 383.28 Mn |
| Jun 30, 2024 | 383.28 Mn |
| Jun 30, 2024 | 383.28 Mn |
| Mar 31, 2024 | 97.58 Mn |
| Mar 31, 2024 | 97.58 Mn |
| Dec 31, 2023 | 43.36 Mn |
| Dec 31, 2023 | 43.36 Mn |